Nurses have had mixed feelings about the rise of artificial intelligence in healthcare, from excitement over its potential for improving care to apprehension about it coming in between them and patients.
Category: Static
Cleveland Clinic investments managing director to exit
Shaun Ng will leave his position as managing director of risk, analytics and operations at Cleveland Clinic’s Investment Office in mid-December, according to a Dec. 4 news release shared with Becker’s.
Florida hospital names CEO
Robert Dahl has been named CEO of Broward Health Imperial Point in Fort Lauderdale, Fla., effective Dec. 2.
MaineHealth names new C-suite leader
Erin Brown has been named vice president of advancement and chief development officer of Portland-based MaineHealth.
Hospital workplace violence is a public health emergency. Why is no one listening?
As many of us scroll through our favorite news app, we are greeted by reports of workplace violence, from verbal and physical confrontations to fatal shootings. What is often missing from the headlines are stories of the increasingly high frequency of …
Tower Health names next CEO
West Reading, Pa.-based Tower Health is preparing for a leadership transition.
'Nurse anesthesiologist' title argument arises in Washington
The District of Columbia’s health department is considering allowing certified registered nurse anesthetists to use the title “nurse anesthesiologist.” Organizations representing healthcare professionals have argued for and against the title change.&nb…
The race to create an oral GLP-1 obesity drug: 4 things to know
The push to develop the first oral GLP-1 receptor drug for obesity is heating up, as three phase 3 drugs race to become the first approved oral treatment for obesity, Global Data reported Dec. 2.
Wisconsin hospitals partner on pediatric cardiology
Madison, Wis.-based UW Health Kids and Milwaukee-based Children’s Wisconsin are forming a joint venture to expand access to pediatric cardiac care.
CMS partners with 2 companies on sickle cell therapies
CMS has reached agreements with bluebird bio and Vertex Pharmaceuticals for their FDA-approved gene therapies for sickle cell disease — Casgevy and Lyfgenia, respectively.
